LifeCell, India’s first and largest private stem cell bank, on May 9 announced its entry into prenatal screening test segment by offering services under the âBabyShieldâ programme to check for treatable but not clinically evident medical conditions in a foetus or embryo in early stages of pregnancy.
This entry is powered by the guidelines powered by LifeCell International acquiring a controlling stake in Fetomed Laboratories, a leading provider of prenatal screening services and foetal medicine, pursuant to the share subscription and purchase agreement signed last week.
With India having the highest incidence of chromosomal disorders in newborns in the world, it becomes even more critical to detect any abnormalities at an early stage through prenatal screening tests. These screening tests will make it easier to detect and prevent the birth of children affected with chromosomal and genetic disorders.
- Quantitative fluorescent polymerase chain reaction (QF-PCR) tests: Introduce QF-PCRÂ as a substitute to the fluorescence in situ hybridization (FISH) technique. QFPCR is a globally accepted and reliable method to detect trisomies with a high-throughput, faster reporting, covers more than 99 per cent of the clinically relevant aneuploidies and very low failure rates.
- Non-invasive prenatal testing (NIPT): Promote NIPT for biochemical screening test result showing a high risk of down syndrome, as it can substantially reduce the number of miscarriages occurring due to invasive diagnostic testing.